forum
NATCOPHARM Share Price Discussion
Natco Pharma Ltd.
Sector: Pharmaceuticals and health care
Sector: Pharmaceuticals and health care
NATCOPHARM Share Price *
* (quote may be delayed)
Pfizer’s Upjohn-Mylan merger may have little impact on India operations
As part of the Upjohn-Mylan deal, the Indian unit of US drug major Pfizer announced on July 30 that it will be transferring six brands to the combined entity.
As part of the Upjohn-Mylan deal, the Indian unit of US drug major Pfizer announced on July 30 that it will be transferring six brands to the combined entity.
moneycontrol.com
Like
reply
Reply
share
Share
Recent posts in NATCOPHARM
Piramal Enterprises dispels rumours about financial biz, files complaint with Sebi
Certain market participants are spreading false/misleading rumours against the company's financial services business in an attempt to create panic among various stakeholders, it said in a regulatory filing.
Certain market participants are spreading false/misleading rumours against the company's financial services business in an attempt to create panic among various stakeholders, it said in a regulatory filing.
Moneycontrol
Like
reply
Reply
share
Share
NATCO PHARMA: CO RECEIVES ESTABLISHMENT INSPECTION REPORT FOR MEKAGUDA'S ACTIVE PHARMACEUTICAL INGREDIENT FACILITY
Like
reply
Reply
share
Share
Natco Pharma gets EIR from USFDA for Hyderabad facility
In a BSE filing, Natco Pharma announced "successful closure of inspection" with the receipt of an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at its active pharmaceutical ingredient (API) facility in Mekaguda Village, near Hyderabad, India.
In a BSE filing, Natco Pharma announced "successful closure of inspection" with the receipt of an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at its active pharmaceutical ingredient (API) facility in Mekaguda Village, near Hyderabad, India.
Moneycontrol
Like
reply
Reply
share
Share
Brokerages initiate coverage on these 8 stocks in September, expect 13-52% return
The market is likely to remain in a tight range due to lack of domestic triggers as well as mixed global cues," Siddhartha Khemka, Head - Retail Research at MOFSL told Moneycontrol.
The market is likely to remain in a tight range due to lack of domestic triggers as well as mixed global cues," Siddhartha Khemka, Head - Retail Research at MOFSL told Moneycontrol.
Moneycontrol
Like
reply
Reply
share
Share
Sell natcopharma below 566 cmp 576 tgt open
For sure call what's app me on 7276280387
Like
reply
Reply
share
Share
BUYYYYYYYYYYYYYYYYYYYY Natco Pharma 565/- sl 558 tr 580/-590
Like
reply
Reply
share
Share